Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CBER Proposes Increasing Cell, Gene Therapy Staff In PDUFA VII

Executive Summary

'Indirect and direct review roles' would be added with user fee funds after the PDUFA program is reauthorized.

You may also be interested in...



COVID-19’s Damage To Gene Therapy Development May Last Years

US FDA's Peter Marks says the field is robust, but hedges on approval predictions for the coming years because of pandemic’s effect.

CBER Will Staff Up With 100 More Reviewers ‘By Hook Or By Crook,’ Marks Says

US biologics center is getting back to regular business now that COVID-19 work is subsiding; director Marks credits acting commissioner Woodcock with using all available mechanisms to staff up.

PDUFA VII Could Increase Transparency Of REMS Release Process

Proposed commitment letter language included a look at eliminating REMS, potentially to more clearly outline the process.

Related Content

Topics

UsernamePublicRestriction

Register

PS143521

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel